Please login to the form below

caplacizumab

This page shows the latest caplacizumab news and features for those working in and with pharma, biotech and healthcare.

atopic dermatitis and asthma therapy Dupixent (dupilumab) and Ablynx’ rare blood disorder product Cablivi (caplacizumab).

Sanofi exits R&D pact with Alnylam on rare disease

Alprolix – and the takeover of Belgian biotech Ablynx last year to claim rights to acquired thrombotic thrombocytopenic purpura (aTTP) therapy Cablivi (caplacizumab).
Sanofi extends growth spurt thanks to Genzyme, Dupixent

from Cablivi (caplacizumab) for acquired thrombotic thrombocytopenic purpura (aTTP), which made its debut in Germany in October.
Sanofi gets US okay for $270,000 blood disorder drug Cablivi

The US approval – which comes a few months after Cablivi (caplacizumab) was cleared in the EU – if for the use of Cablivi in combination with plasma exchange and immunosuppressive therapy in
As France protests, Sanofi takes axe to 670 jobs

dermatitis therapy Dupixent (dupilumab), checkpoint inhibitor Libtayo (cemiplimab) for cutaneous squamous cell carcinoma (CSCC) and Cablivi(caplacizumab) for acquired thrombotic thrombocytopenic purpura.
Dupixent helps put Sanofi back on growth track

Brandicourt is also hoping for new sales momentum from two new product approvals – checkpoint inhibitor Libtayo (cemiplimab) for cutaneous squamous cell carcinoma (CSCC) and Cablivi (caplacizumab) for acquired thrombotic thrombocytopenic purpura

More from news
Approximately 2 fully matching, plus 15 partially matching documents found.

Deal Watch January 2018

bid for Ablynx in December, which the Ablynx Board rejected. Novo Nordisk's particular interest was in lead asset caplacizumab, a Nanobody therapeutic which inhibits von Willebrand factor (vWF) for the ... Acquisition company. 7, 000. Ablynx/Sanofi.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Novo Nordisk target Ablynx reshuffles its board

lead, wholly-owned product, caplacizumab, in addition to advancing our extensive pipeline.”.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Publications Director, Medical Communications agency, Cambridge: Competitive Salary

Client Partner, Healthcare Brand Communications, London: Highly competitive package

Publications Director, Medical Communications agency, Oxford: Competitive Salary

Publications Director, Medical Communications agency, Home Based...: Competitive Salary

Add my company

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Precision paediatrics: Treating patients with CAR-T: Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation: We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2): Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...